bpc 157 labs The Human Lab Rats Injecting Themselves with Peptides | Office for Science and Society BPC-157 + TB-500 – NovaPepta

Conclusion: A lower T-cell content in thrombi retrieved during EVT from AIS patients was associated with poorer clinical outcome, indicating a possible role of inflammation in outcome after LVO stroke

Compound Receptors Peak trial weight loss Lean mass as share of loss Semaglutide (Ozempic/Wegovy) GLP-1 ~14.9% (STEP-1, 68 wk) ~39% Tirzepatide (Mounjaro/Zepbound) GLP-1 + GIP ~20.9% (SURMOUNT-1, 72 wk) ~25-40% Retatrutide GLP-1 + GIP + GCGR ~24.2% (Phase 2, 48 wk) Comparable class range Best for understanding the takeaway: the percentage of loss that is lean mass is roughly constant across the class

Wegovy vs

The logic is appealing